lundi 30 juillet 2018

Onco Actu du 30 juillet 2018

1. Biologie

Scientists Identify Growth Signal for Metastatic Cancer "Seeds" [Memorial Sloan Kettering Cancer Center]

5. Traitements

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature [European Journal of Cancer]

5.12 Immunothérapies

Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and Helen Chen [NCI]

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” [Labiotech]

5.12.5 Immunothérapies - Pharma

Bristol-Myers Drops After Cancer Drug Combo Rejected in Europe [Bloomberg]

Bristol-Myers takes another hit on Opdivo/Yervoy combo as CHMP turns thumbs down on frontline kidney cancer [EndPoints]

5.12.6 Immunothérapies - AMM

Imfinzi receives positive EU CHMP opinion for locally-advanced, unresectable non-small cell lung cancer [AstraZeneca]

AstraZeneca's key lung cancer drug wins European panel thumbs-up [Reuters]

5.12.8 Immunothérapies - Economie

Immunotherapy drug made available for some NHS patients with Hodgkin lymphoma [Cancer Research UK]

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma [Novartis]

EMA restricts use of prostate cancer medicine Xofigo [EMA]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018 [EMA]

5.5 ASCO

From Cattle Rancher to ASCO President [Medpage Today]

6.7.1 IA/bioinformatique

The Real Future Of Artificial Intelligence And Cancer [Forbes]

IBM Watson recommended ‘unsafe’ cancer treatments, according to internal documents [The Daily Dot]